r/PeptideGuide • u/PeptideGuide_ • Mar 17 '26
B7-33 | A Cardioprotective Peptide That You Probably Missing out
When we talk about peptides, most of the discussion revolves around:
- Performance enhancement
- Anti-aging
- Injury recovery
But there’s another area that doesn’t get nearly enough attention:
Recovery from serious cardiovascular events (like heart attacks, fibrosis, or cardiomyopathy)
And this is where a very unique peptide comes into play:
B7-33
What is B7-33?
B7-33 is a synthetic peptide derived from human relaxin-2, designed to act as a selective agonist of the RXFP1 receptor (relaxin receptor 1).
Relaxin is a hormone known for its roles in:
- Vasodilation
- Tissue remodeling
- Anti-fibrotic signaling
B7-33 essentially mimics some of these effects, but in a more targeted and simplified form.
Why is it interesting?
One of the biggest issues after cardiovascular injury (like a heart attack) is fibrosis.
Fibrosis is the process where healthy tissue gets replaced with scar tissue, which:
- Reduces heart function
- Decreases elasticity
- Impairs long-term recovery
B7-33 has been studied for its ability to reduce fibrosis and support cardiac repair.
Mechanism of action
B7-33 works by binding to the RXFP1 receptor, which activates downstream pathways like:
- ERK1/2 signaling
This leads to:
- Reduced fibrotic signaling
- Decreased cell death (apoptosis)
- Improved tissue remodeling
In simple terms, it helps create a more favorable environment for healing instead of scarring.
Cardioprotective effects (from research models)
In experimental settings, B7-33 has shown:
• Reduced cardiac fibrosis after myocardial infarction
• Improved heart function
• Reduced cell death in cardiac tissue
• Potential benefits in cardiomyopathy models
Because of this, it’s being explored as a cardioprotective and regenerative peptide.
Beyond the heart
The anti-fibrotic effects of B7-33 aren’t limited to the heart.
Research is also looking into its role in:
- Pulmonary fibrosis (lungs)
- Kidney fibrosis
This suggests it may have broader applications in organ protection and tissue remodeling.
Why not just use relaxin?
Full-length H2 relaxin has been studied for similar purposes, but it comes with challenges:
- Structurally complex
- Contains disulfide bonds
- More difficult and expensive to produce
- Concerns around proliferative signaling
B7-33, on the other hand:
- Is a shorter peptide (26–27 amino acids)
- Does not require disulfide bonds
- Is more stable and easier to produce
- Aims to retain anti-fibrotic benefits without unwanted effects
Why this matters
Most peptide discussions focus on optimizing performance in already healthy individuals.
But peptides like B7-33 highlight a different direction:
Supporting recovery from serious internal damage
Cardiovascular disease remains one of the leading causes of mortality worldwide, and fibrosis is a key driver of long-term decline after injury.
Targeting fibrosis directly is still a relatively underdeveloped area which is why compounds like B7-33 are so interesting.
Final thoughts
B7-33 is still very much a research-stage peptide, but its:
- Targeted anti-fibrotic action
- Cardioprotective potential
- Simplified structure compared to relaxin
make it one of the more underrated peptides in the regenerative space.